Your browser doesn't support javascript.
loading
Novel strategies exploiting interleukin-12 in cancer immunotherapy.
Cirella, Assunta; Luri-Rey, Carlos; Di Trani, Claudia Augusta; Teijeira, Alvaro; Olivera, Irene; Bolaños, Elixabet; Castañón, Eduardo; Palencia, Belen; Brocco, Davide; Fernández-Sendin, Myriam; Aranda, Fernando; Berraondo, Pedro; Melero, Ignacio.
Afiliação
  • Cirella A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
  • Luri-Rey C; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
  • Di Trani CA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
  • Teijeira A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Department of oncology, Clinica Universidad de Navarra, Madrid, Spain.
  • Olivera I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
  • Bolaños E; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
  • Castañón E; Department of oncology, Clinica Universidad de Navarra, Madrid, Spain.
  • Palencia B; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
  • Brocco D; Department of Pharmacy, University "G. D'Annunzio" Chieti-Pescara, Chieti, Italy.
  • Fernández-Sendin M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
  • Aranda F; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
  • Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain.
  • Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Department of oncology, Clinica Universidad de Navarra, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain; Departm
Pharmacol Ther ; 239: 108189, 2022 11.
Article em En | MEDLINE | ID: mdl-35430292
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-12 / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Pharmacol Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-12 / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Pharmacol Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha